Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 9/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083411 | 0.73 | RPS6KA3 (0.52) | CYP2D6RPS6KA3RPS6KA2 | |
| SCHEMBL3088114 | 0.71 | RPS6KA3 (0.67) | RPS6KA3RPS6KA2 | |
| SCHEMBL1982385 | 0.70 | RPS6KA2 (0.45) | RPS6KA3RPS6KA2 | |
| SCHEMBL1980016 | 0.69 | RPS6KA3 (0.79) | RPS6KA3RPS6KA2 | |
| SCHEMBL25118592 | 0.69 | CHRNB2 (0.35) | CYP2D6PARP1 | |
| SCHEMBL1980033 | 0.67 | RPS6KA3 (0.63) | RPS6KA3RPS6KA2 | |
| SCHEMBL1979617 | 0.67 | RPS6KA3 (0.48) | RPS6KA3RPS6KA2 | |
| SCHEMBL3080179 | 0.66 | RPS6KA2 (0.54) | RPS6KA3RPS6KA2PARP1 | |
| SCHEMBL1979447 | 0.66 | RPS6KA2 (0.41) | RPS6KA3RPS6KA2 | |
| SCHEMBL3574670 | 0.66 | SRD5A2 (0.50) | RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110746424-A | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | HRH3 3521/4885CYP2D6 2278/4885RPS6KA3 75/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | HRH3 3521/4885CYP2D6 2278/4885RPS6KA3 75/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | HRH3 3521/4885CYP2D6 2278/4885RPS6KA3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.